BNP Paribas Financial Markets
ANIX icon

BNP Paribas Financial Markets’s Anixa Biosciences ANIX Stock Holding History

BNP Paribas Financial Markets’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,140
Closed -$28.5K – 5819
2025
Q4 		$28.5K Buy
+9,140
New +$37.4K ﹤0.01% 4921
2022
Q4 		– Sell
-97
Closed -$477 – 4063
2022
Q3 		$477 Buy
+97
New +$393 ﹤0.01% 4523

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BNP Paribas Financial Markets's ANIX Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 9,140 shares — an estimated $28.5K sold.

BNP Paribas Financial Markets first reported a position in ANIX in Q3 2022 and held it in 2 quarters. The position peaked at $28.5K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 9,140 Anixa Biosciences shares in Q1 2026, an estimated $28.5K.
  • BNP Paribas Financial Markets first reported a position in Anixa Biosciences in Q3 2022 and held it in 2 quarters.
  • BNP Paribas Financial Markets's Anixa Biosciences position peaked at $28.5K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.